AR127012A1 - Proceso para formular composiciones que comprenden análogos de péptido-2-similar-a-glucagón (glp-2) - Google Patents
Proceso para formular composiciones que comprenden análogos de péptido-2-similar-a-glucagón (glp-2)Info
- Publication number
- AR127012A1 AR127012A1 ARP220102435A ARP220102435A AR127012A1 AR 127012 A1 AR127012 A1 AR 127012A1 AR P220102435 A ARP220102435 A AR P220102435A AR P220102435 A ARP220102435 A AR P220102435A AR 127012 A1 AR127012 A1 AR 127012A1
- Authority
- AR
- Argentina
- Prior art keywords
- glp
- peptide
- analogs
- compositions including
- formulating compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- DOAUQKRTILFGHV-PDCMDPCFSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S,3S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O DOAUQKRTILFGHV-PDCMDPCFSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 229950001278 elsiglutide Drugs 0.000 abstract 1
- 229940057954 glepaglutide Drugs 0.000 abstract 1
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Procesos para producir una formulación farmacéutica líquida estable que comprende un análogo de péptido 2 similar-a-glucagón (GLP-2), y en particular procesos para producir formulaciones que comprenden ZP1848 (glepaglutida) o ZP1846 (elsiglutida) basadas en una formulación de un solo recipiente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21196169 | 2021-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127012A1 true AR127012A1 (es) | 2023-12-06 |
Family
ID=77989732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102435A AR127012A1 (es) | 2021-09-10 | 2022-09-08 | Proceso para formular composiciones que comprenden análogos de péptido-2-similar-a-glucagón (glp-2) |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4398872A1 (es) |
| JP (1) | JP2024531634A (es) |
| KR (1) | KR20240055083A (es) |
| CN (1) | CN118055757A (es) |
| AR (1) | AR127012A1 (es) |
| AU (1) | AU2022341538A1 (es) |
| CA (1) | CA3231402A1 (es) |
| CL (1) | CL2024000603A1 (es) |
| IL (1) | IL311317A (es) |
| MX (1) | MX2024002569A (es) |
| TW (1) | TW202327643A (es) |
| WO (1) | WO2023036862A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| SE518469C2 (sv) | 2001-02-12 | 2002-10-15 | Scania Cv Ab | Förfarande och system för fastställande av tankvolym |
| NZ591178A (en) | 2005-05-04 | 2012-06-29 | Zealand Pharma As | Glucagon-like-peptide-2 (glp-2) analogues |
| DK3638291T3 (da) | 2017-06-16 | 2021-10-18 | Zealand Pharma As | Dosisregimer til indgivelse af glucagon-lignende-peptid-2 (GLP-2)-analoger |
| EP3628682A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| EP3628683A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
-
2022
- 2022-09-08 CA CA3231402A patent/CA3231402A1/en active Pending
- 2022-09-08 IL IL311317A patent/IL311317A/en unknown
- 2022-09-08 MX MX2024002569A patent/MX2024002569A/es unknown
- 2022-09-08 JP JP2024515377A patent/JP2024531634A/ja active Pending
- 2022-09-08 WO PCT/EP2022/074961 patent/WO2023036862A1/en active Application Filing
- 2022-09-08 AU AU2022341538A patent/AU2022341538A1/en active Pending
- 2022-09-08 CN CN202280061254.7A patent/CN118055757A/zh active Pending
- 2022-09-08 KR KR1020247011554A patent/KR20240055083A/ko unknown
- 2022-09-08 EP EP22765583.4A patent/EP4398872A1/en active Pending
- 2022-09-08 AR ARP220102435A patent/AR127012A1/es unknown
- 2022-09-08 TW TW111134097A patent/TW202327643A/zh unknown
-
2024
- 2024-02-28 CL CL2024000603A patent/CL2024000603A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118055757A (zh) | 2024-05-17 |
| KR20240055083A (ko) | 2024-04-26 |
| IL311317A (en) | 2024-05-01 |
| CA3231402A1 (en) | 2023-03-16 |
| WO2023036862A1 (en) | 2023-03-16 |
| CL2024000603A1 (es) | 2024-08-16 |
| MX2024002569A (es) | 2024-04-30 |
| AU2022341538A1 (en) | 2024-04-11 |
| JP2024531634A (ja) | 2024-08-29 |
| EP4398872A1 (en) | 2024-07-17 |
| TW202327643A (zh) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241760A1 (es) | Compuestos antivirales que contienen nitrilo | |
| ES2158988T3 (es) | Composiciones de aerosol. | |
| HRP20050690A2 (en) | Hiv inhibiting 1,2,4-triazines | |
| PA8559501A1 (es) | Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno | |
| UY27137A1 (es) | Métodos para administrar análogos de epotilona en el tratamiento del cáncer | |
| AR059723A2 (es) | Composicion de altas dosis de ibandronato | |
| CL2021000678A1 (es) | Formulaciones de análogos del péptido similar a glucagón tipo 2 (glp-2) | |
| PH12020551841A1 (en) | Stable pharmaceutical formulation | |
| CL2008002356A1 (es) | Sulfoxidos de piperazina-amida; sus procesos de preparacion; las composiciones farmaceuticas que los contienen; y su uso en el tratamiento de enfermedades que se modulan con agonistas lxr alfa y/o beta. | |
| ECSP077262A (es) | Composicion antihistaminica | |
| AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
| AR127012A1 (es) | Proceso para formular composiciones que comprenden análogos de péptido-2-similar-a-glucagón (glp-2) | |
| CO2023010010A2 (es) | Composición farmacéutica que comprende un derivado de difenilpirazina | |
| AR099963A2 (es) | Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenar | |
| NO20084478L (no) | Konjugerte lipidderivater | |
| AR021921A1 (es) | Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido. | |
| PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| JP2018024662A (ja) | 眼科組成物 | |
| AR043412A1 (es) | Formulaciones farmaceuticas que comprenden un agente enmascarante del sabor amargo | |
| DOP2022000004A (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
| AR040242A1 (es) | Composiciones farmaceuticas | |
| PE20030098A1 (es) | Capsulas elasticas blandas y composiciones de las mismas | |
| AR128113A1 (es) | Composiciones que contienen fexofenadina | |
| JP2018035151A (ja) | 眼科組成物 | |
| JP2018016607A (ja) | 複合目症状改善用眼科組成物 |